• Home
  •  / Twist Bioscience

Twist Bioscience

OverviewSuggest Edit

Twist Bioscience is a synthetic biology company that develops a proprietary silicon-based manufacturing process for the production of synthetic DNA. It manufactures a range of synthetic DNA-based products, including synthetic genes, tools for next generation sample preparation, as well as antibody libraries for drug discovery and development. Additionally, the company focuses on discovery partnerships for biologic drugs, and new applications for synthetic DNA, such as digital data storage. Twist Bioscience serves the medicine, agriculture, industrial chemicals, and data storage markets.

TypePublic
HQSouth San Francisco, CA, USMap
Websitetwistbioscience.com
Employee Ratings4.2More
Overall CultureA-More
View Jobs (80)

Recent NewsAll News

Latest Updates

Employees (est.) (Sept 2020)525(+27%)
Job Openings80
Revenue (FY, 2020)$90.1 M(+66%)
Share Price (May 2021)$116.7(-3%)
Cybersecurity ratingBMore

Key People/Management at Twist Bioscience

Emily Leproust

Emily Leproust

CEO and Co-Founder, Board Member
Jim Thorburn

Jim Thorburn

Chief Financial Officer
Patrick Weiss

Patrick Weiss

Chief Operating Officer
Patrick Finn

Patrick Finn

Chief Commercial Officer
Aaron Sato

Aaron Sato

Chief Scientific Officer
Siyuan Chen

Siyuan Chen

Chief Technology Officer
Show more

Twist Bioscience Office Locations

Twist Bioscience has offices in South San Francisco, Carlsbad, San Francisco, Guangzhou Shi and in 2 other locations
South San Francisco, CA, US (HQ)
681 Gateway Blvd
Carlsbad, CA, US
5600 Avenida Encinas Suite 140D-2
San Francisco, CA, US
500 Terry A Francois Blvd, San Francisco
Guangzhou Shi, CN
Guanzhou Life Science Innovation Center North Tower, Second Floor, Room 203
Tel Aviv-Yafo, IL
Rothschild Blvd 3
Singapore, SG
3 Fusionopolis Pl
Show all (6)

Twist Bioscience Financials and Metrics

Twist Bioscience Revenue

Embed Graph
View revenue for all periods
Twist Bioscience's revenue was reported to be $90.1 m in FY, 2020
USD

Revenue (Q1, 2021)

28.2m

Gross profit (Q1, 2021)

10.0m

Gross profit margin (Q1, 2021), %

35.5%

Net income (Q1, 2021)

(32.9m)

EBIT (Q1, 2021)

(32.8m)

Market capitalization (7-May-2021)

5.7b

Closing stock price (7-May-2021)

116.7

Cash (31-Dec-2020)

348.8m

EV

5.4b
Twist Bioscience's current market capitalization is $5.7 b.
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Revenue

2.3m10.8m54.4m90.1m

Revenue growth, %

375%

Cost of goods sold

9.4m24.0m47.4m61.4m

Gross profit

(7.2m)(13.3m)7.0m28.7m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.7m2.4m3.2m4.3m6.2m6.5m11.5m13.6m13.6m17.2m19.3m21.2m28.2m

Cost of goods sold

5.0m6.0m6.2m7.5m8.1m7.5m11.9m11.8m11.4m13.8m13.6m16.5m18.2m

Gross profit

(3.3m)(3.6m)(3.0m)(3.2m)(1.9m)(962.0k)(365.0k)1.8m2.2m3.4m5.7m4.7m10.0m

Gross profit Margin, %

(195%)(146%)(96%)(74%)(31%)(15%)(3%)13%16%20%30%22%36%
show all
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Cash

28.6m31.2m46.7m93.7m

Accounts Receivable

723.0k2.3m12.1m26.4m

Prepaid Expenses

1.2m1.5m2.6m6.2m

Inventories

1.2m1.8m7.3m12.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

66.5m28.7m68.2m26.0m184.4m207.9m348.8m

Accounts Receivable

7.0m8.0m11.7m13.1m14.8m13.3m25.5m

Prepaid Expenses

4.0m4.2m3.6m5.7m4.5m6.3m8.2m

Inventories

5.6m4.4m5.5m7.4m10.8m13.2m13.4m
show all
Annual
USDFY, 2016FY, 2017FY, 2019FY, 2020

Net Income

(44.1m)(59.3m)(107.7m)(139.9m)

Depreciation and Amortization

4.2m5.0m6.1m6.7m

Inventories

(1.2m)(599.0k)(1.3m)(5.0m)

Accounts Payable

466.0k560.0k3.3m(5.5m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(22.6m)(48.6m)(76.5m)(55.6m)(87.4m)(115.6m)(32.9m)

Depreciation and Amortization

1.5m3.0m4.6m1.5m3.1m4.8m2.1m

Inventories

467.0k1.6m532.0k(86.0k)(3.4m)(5.8m)(1.1m)

Accounts Payable

(715.0k)(2.0m)(96.0k)(556.0k)(3.1m)(3.8m)3.5m
show all
USDFY, 2016

Financial Leverage

-1 x
Show all financial metrics

Twist Bioscience Operating Metrics

Twist Bioscience's Customers was reported to be 539 in Q3, 2018.
Q3, 2016Q4, 2016Q1, 2017Q2, 2017Q3, 2017Q4, 2017Q1, 2018Q2, 2018Q3, 2018

Customers

539

Order Volume

$753 k$2.31 m$2.73 m$4.21 m$4.43 m$6.19 m$7.39 m$8.52 m$10.67 m

Shipments

7519641.25 k1.69 k
Show all operating metrics

Twist Bioscience Revenue Breakdown

Embed Graph

Twist Bioscience revenue breakdown by business segment: 75.4% from Synthetic genes, 19.1% from Oligo pools and 5.5% from Other

Twist Bioscience revenue breakdown by geographic segment: 76.6% from United States, 18.8% from EMEA and 4.7% from Other

Twist Bioscience Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

Learn more about our premium products
SecurityScorecard logo

Twist Bioscience Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Twist Bioscience Online and Social Media Presence

Twist Bioscience's Trends

Embed Graph

Twist Bioscience Company Culture

  • Overall Culture

    A-

    83/100

  • CEO Rating

    A+

    95/100

  • Compensation

    C+

    70/100

Learn more on Comparably

Twist Bioscience News and Updates

October 27, 2020

ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products

VICTORIA, BC, Oct. 27, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary, Talem Therapeutics, entered into a...
June 14, 2017

DNA synthesis provider Twist Bioscience attracts $27 mln

San Francisco-based Twist Bioscience, a provider of DNA synthesis, has raised $27 million in funding. The investors were Biomatics Capital, Reinet Fund S.C.A., F.I.S., NFT Investment Limited, KANGMEI Group, Bay City Capital GF Xinde Life Science Investment Fund, 3W Partners Capital and Ditch Plains …

Twist Bioscience Blogs

December 03, 2020

Pierre Martineau, Deputy Director of the IRCM

Pierre Martineau, Deputy Director of the IRCM We have performed the first selections using the Fab and scFv libraries. No problem in both cases, we got clones and some look really promising. rlevi Thu, 12/03/2020 - 08:29 Cancer Research Institute of Montpellier and i…
December 03, 2020

DR. AHUVA NISSIM PROFESSOR IN ANTIBODY AND THERAPEUTIC ENGINEERING

DR. AHUVA NISSIM PROFESSOR IN ANTIBODY AND THERAPEUTIC ENGINEERING Working with Twist...was a great experience...[Twist’s] support was amazing. We have performed the first validation selections which looks promising... rlevi Thu, 12/03/2020 - 07:14 PROFESSOR IN ANTIBO…
July 13, 2020

Erin Smith

Erin Smith rlevi Mon, 07/13/2020 - 03:33 Erin joined Twist in June 2020, bringing demonstrated leadership in furthering industry agendas by working with key stakeholders and government officials. Previously, Erin led the expansion of a government affairs program at Gilead Sciences. Befo…
February 19, 2020

Twist is coming to Dublin

Twist is coming to Dublin cthorne Tue, 02/18/2020 - 23:28 Join us at the Teeling Whisky Distillery in Dublin on the 11th September to learn more about what you can do with our transformative silicon-based DNA synthesis technology, and to meet other like-minded prof…
February 13, 2020

ABRF 2020 Annual meeting

ABRF 2020 Annual meeting rlevi Thu, 02/13/2020 - 01:30 Association of Biomolecular Resource Facilities   Palm Spring, CA Feb 29, 2020 - Mar 3, 2020
February 10, 2020

The Raw Materials to Tackle Coronavirus

The Raw Materials to Tackle Coronavirus rlevi Mon, 02/10/2020 - 00:55 The coronavirus that recently emerged from Wuhan, China, is a major public health threat, infecting tens of thousands and killing hundreds, so far. While the Wuhan coronavirus (2019-nCoV) is mostly localized to China, it has sp…
Show more

 Twist Bioscience Frequently Asked Questions

  • Who are Twist Bioscience key executives?

    Twist Bioscience's key executives are Emily Leproust, Jim Thorburn and Patrick Weiss.

  • How many employees does Twist Bioscience have?

    Twist Bioscience has 525 employees.

  • What is Twist Bioscience revenue?

    Latest Twist Bioscience annual revenue is $90.1 m.

  • What is Twist Bioscience revenue per employee?

    Latest Twist Bioscience revenue per employee is $171.6 k.

  • Who are Twist Bioscience competitors?

    Competitors of Twist Bioscience include Promega, Eurofins Genomics and Integrated DNA Technologies.

  • Where is Twist Bioscience headquarters?

    Twist Bioscience headquarters is located at 681 Gateway Blvd, South San Francisco.

  • Where are Twist Bioscience offices?

    Twist Bioscience has offices in South San Francisco, Carlsbad, San Francisco, Guangzhou Shi and in 2 other locations.

  • How many offices does Twist Bioscience have?

    Twist Bioscience has 6 offices.